摘要
黑素瘤是常见的皮肤恶性肿瘤,其恶性程度高,侵袭性强,患者预后极差。但自2011年以来多个新药陆续上市,尤其是免疫治疗药物优势凸显。例如,CTLA-4抗体药物(ipilimumab)和PD-1/PD-L1抗体药物(nivolumab,pembrolizumab)大幅提高黑素瘤患者的客观有效率;IL-2瘤内给药和L19-IL2融合蛋白药物也取得令人瞩目的临床进展。本文从免疫检查点抑制剂、被动免疫、主动免疫、过继免疫等方面,对迄今已上市和即将上市的黑素瘤免疫治疗药物进行介绍,利于临床用药,也为新药研发提供思路。
Metastatic melanoma is a common, highly malignant, and invasive disease with extremely poor prognosis. Since 2011, many new drugs have been on the market, especially immunological therapy drugs with advantage of curative effect. For example, anti-CTLA-4 antibody （ipilimumab） and anti-PD-1 antibodies （ nivolumab and pembrolizumab） increase the objective response rate of metastatic melanoma, and the intralesional administration of IL-2 and the L19-IL2 fusion protein drug totally create remarkable clinical trial results. Here, we introduced the new melanoma immunotherapy drugs like immune checkpoint inhibitors, passive immunization, active immunization, and adoptive immunotherapy, which will be helpful for clinical use of the drugs as well as new drug development.
出处
《中国新药杂志》
CAS
CSCD
北大核心
2016年第22期2569-2573,共5页
Chinese Journal of New Drugs
